Specialty apis, as the backbone of the API field, are significantly different from traditional bulk apis. It focuses on drugs whose patents have not yet expired or those with special therapeutic needs. The research and development and manufacturing are highly challenging, and the technical barriers are as solid as a rock, which also endows it with a relatively high added value. From the perspective of application scope, characteristic apis are widely involved in numerous therapeutic fields such as anti-tumor, cardiovascular, and mental and neurological treatments. These fields are closely related to the core needs of human health and have extremely strict requirements for the efficacy and safety of drugs. ​

Take anti-tumor drugs as an example. The precision and purity of characteristic raw materials directly affect the therapeutic effect of anti-cancer drugs and the quality of life of patients. Globally, with the acceleration of the aging process of the population and the rising incidence of chronic diseases, the market demand for characteristic apis is showing a rapid growth trend. According to relevant data, in the past few years, the global market size of specialty apis has been steadily expanding at an annual rate of [X]%, demonstrating strong market vitality and potential. ​

In recent years, China has made considerable progress in the field of characteristic active pharmaceutical ingredients. Domestic enterprises, relying on their continuously enhanced R&D capabilities and technological innovation, have gradually broken the international monopoly pattern, emerged in the international market, and their market share has continued to expand. However, we must also clearly recognize that the development of the industry has not been smooth sailing and still faces many severe challenges. On the one hand, international market competition is becoming increasingly fierce. Pharmaceutical companies from various countries are all increasing their investment in research and development to compete for the limited market resources. On the other hand, the drug regulatory authorities have increasingly strict requirements for the quality standards and safety of characteristic raw materials, which poses a higher-level test to the production processes and quality management systems of enterprises. ​

In this industry wave full of opportunities and challenges, Chuzhou Qingyun Pharmaceutical Co., Ltd. stands at the forefront and actively engages in the research and development and production of characteristic raw materials. Since its establishment in 2016, the company has always regarded innovation as the core driving force for its development. It has formed a professional R&D team led by senior scientific research experts. Team members, relying on their profound professional knowledge and rich practical experience, focus on the cutting-edge technology research and process optimization of characteristic active pharmaceutical ingredients. At present, the company has made significant breakthroughs in multiple characteristic raw material drug varieties. The key technical indicators of some products have reached the international advanced level. Not only has the goal of domestic substitution for imported products been achieved, but it has also successfully entered the international market and won high praise and trust from domestic and foreign customers.